Business Wire

ExaGrid Wins “Storage Company of the Year” and “Vendor Channel Program of the Year” at 13th Annual 2022 SDC Awards

29.11.2022 16:00:00 EET | Business Wire | Press release

Share

ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with two awards at the 13th annual SDC Awards ceremony, Angel Business Communications’ premier IT awards – the Storage, Digitalisation + Cloud Awards, held in London on November 24, 2022. ExaGrid won “Storage Company of the Year” and “Vendor Channel Program of the Year,” making it the third year in a row for each. These new award wins add to ExaGrid’s previous four wins this past fall, totaling six industry awards in 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005098/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ExaGrid Wins “Storage Company of the Year” at 13th Annual 2022 SDC Awards (Photo: Business Wire)

ExaGrid’s Reseller Partner Program won “Vendor Channel Program of the Year.” ExaGrid offers one of the best deal registration programs in the industry to drive high margins along with deal SPIFFs and meeting maker bonuses. In addition, ExaGrid offers an optional Solutions Architects certification at no charge to become an ExaGrid Certified Solutions Architect. ExaGrid works with resellers and distributors worldwide and has customer installations in over 80 countries. The ExaGrid programs are designed to be easy for partners, with full support from the ExaGrid sales team - resulting in a 75% competitive win rate. ExaGrid is known for having a Tiered Backup Storage system that is highly differentiated and provides its customers with stellar customer support from an assigned level 2 engineer, ensuring that partners’ customers receive class “A” support.

ExaGrid also won “Storage Company of the Year” for the third year in a row. In 2021, ExaGrid expanded its product line with greater scalability up to 2.7PB full backup to a single system. In 2022, ExaGrid announced its Cloud Tier for Disaster Recovery in AWS and Azure as well as 30X faster Veeam synthetic fulls, improvements to its Retention Time-Lock features for ransomware recovery, and many other new features. ExaGrid has advanced IT tools and calculators to further assist a customer in calculating the true cost of backup storage up front and over time. These tools show customers what their costs of backup storage will be - inclusive of backup rotation, backup retention, yearly data growth, and second site disaster recovery.

ExaGrid has had back-to-back record quarters in 2022 and has expanded its customer base to over 3,600 customers in over 80 countries. ExaGrid continues to be cash positive, EBITDA positive, and P&L positive quarter after quarter. ExaGrid is the only company that is completely dedicated to backup storage, with a goal to solve the issues commonly experienced with backup solutions while providing the best value to its customers, including the fastest backups, fastest restores, a fixed length backup window as data grows, comprehensive security including ransomware recovery and low cost up front and overtime.

“These two awards simply say it all. We apply 100% of our focus on serving our channel partners with our Tiered Backup Storage offering,” said Bill Andrews, President and CEO of ExaGrid. “Congratulations to all the 2022 winners! We are certainly in good company. Since these awards are voted on by the public, it means a great deal to us. We will continue to push the limits with our Tiered Backup Storage solution and expert-level support.”

ExaGrid continues to gain recognition for its Tiered Backup Storage appliances, winning six awards in 2022, which is the most for any backup storage provider in 2022, including:

  • SDC Awards – Storage Company of the Year
  • SDC Awards – Vendor Channel Program of the Year
  • Storage Awards – Enterprise Backup Hardware Vendor of the Year
  • Network Computing Awards – Bench Tested Product of the Year
  • Network Computing Awards – Company of the Year
  • Network Computing Awards – Storage Product of the Year

This is the 3rd year in a row that ExaGrid won more backup storage provider awards than any other vendor.

ExaGrid Tiered Backup Storage

ExaGrid provides Tiered Backup Storage with a front-end disk-cache Landing Zone, which writes data directly to disk for the fastest backups and restores directly from disk for the fastest restores and VM boots. The long-term retention data is tiered to a deduplicated data repository, the Retention Tier, to reduce the amount of retention storage and resulting cost. This two-tiered approach provides the fastest backup and restore performance with the lowest cost storage efficiency.

In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades and allows for mixing appliances of different sizes and models in the same scale-out system, which eliminates product obsolescence while protecting IT investments up front and over time.

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, India, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories . Check out our 100+ Gartner Peer Insight Reviews . ExaGrid is proud of our +81 NPS score.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye